4-propan-2-yl-2,3-dihydro-1H-imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 4-propan-2-yl-2,3-dihydro-1H-imidazole
• 化学式: C₆H₁₂N₂
• 分子量: 112.17
• InChiKey: XJSVFGYCUZPTIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：Seragon Pharmaceuticals, Inc.

  公开号：US20150105403A1

  公开（公告）日：2015-04-16

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了一些雌激素受体调节剂化合物。还描述了包括上述化合物的制药组合物和药物，以及使用这些雌激素受体调节剂，单独或与其他化合物联合治疗介导或依赖于雌激素受体的疾病或病情的方法。
• Receptor antagonists
  申请人：Proximagen Limited

  公开号：EP2927224A1

  公开（公告）日：2015-10-07

  The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.

  式（I）化合物是 CXCR4 受体的拮抗剂 其中 R1、X、Y 和 R2 如权利要求中所定义。
• DIHYDROCHROMENE DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：EP3770162A1

  公开（公告）日：2021-01-27

  The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.

  本发明涉及式(I)化合物，其中R1A、R1B、R1C和R1D为氢原子等，R2A和R2B为氢原子等，R3A、R3B、R3C和R3D为氢原子等，L为键等、V是C1-6亚烷基，Q是任选取代的咪唑或其药学上可接受的盐，作为一种新型抗肿瘤药，靶向CSCs，CSCs被认为与恶性肿瘤的持续增殖、癌症的转移或复发以及对抗肿瘤药的耐药性密切相关。
• METHODS AND COMPOSITIONS FOR MODULATING SPLICING
  申请人：Skyhawk Therapeutics, Inc.

  公开号：US20220048902A1

  公开（公告）日：2022-02-17

  Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.
• US9499538B2
  申请人：——

  公开号：US9499538B2

  公开（公告）日：2016-11-22